FDA Finds Creative Labeling Solution For Egrifta Patient-Reported Outcomes Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA faces a challenge when it receives results from a patient-reported outcomes tool that it does not think is properly validated, but was designed in consultation with the agency.